Your browser is no longer supported. Please, upgrade your browser.
IMMP Immutep Limited daily Stock Chart
Immutep Limited
Index- P/E- EPS (ttm)-0.40 Insider Own- Shs Outstand38.88M Perf Week-1.78%
Market Cap27.49M Forward P/E- EPS next Y- Insider Trans- Shs Float35.76M Perf Month-66.80%
Income- PEG- EPS next Q- Inst Own1.71% Short Float2.78% Perf Quarter-62.59%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio2.83 Perf Half Y-57.40%
Book/sh0.80 P/B0.88 EPS next Y- ROA- Target Price7.41 Perf Year-65.51%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range0.53 - 3.10 Perf YTD-60.50%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-77.19% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low33.42% ATR0.18
Employees- Current Ratio- Sales Q/Q320.70% Oper. Margin- RSI (14)27.80 Volatility7.62% 15.47%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume1.07 Prev Close0.74
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume351.27K Price0.71
Recom2.00 SMA20-42.30% SMA50-64.34% SMA200-59.88% Volume377,043 Change-4.45%
Sep-28-18Initiated B. Riley FBR Buy $7.75
Feb-15-18Reiterated Maxim Group Buy $7 → $5
Apr-08-20 08:00AM  Immuteps Partner, EOC Pharma, Continues to Advance Efti in Breast Cancer GlobeNewswire
Mar-24-20 09:35PM  Immutep Reports Supportive Efficacy Data from the Phase IIb AIPAC Study; Overall Survival Data Expected in Late 2020 GlobeNewswire +5.11%
Mar-19-20 08:02PM  Immuteps Partner, EOC Pharma, Reports Completion of Recruitment of Phase I Study of Efti GlobeNewswire -6.04%
Mar-17-20 05:42PM  The Non-Executive Director of Immutep Limited (ASX:IMM), Grant Chamberlain, Just Bought 38% More Shares Simply Wall St. +10.29%
Mar-09-20 08:00AM  Immutep Receives Second IND approval for Efti from US FDA GlobeNewswire -10.00%
Feb-19-20 08:00AM  Immutep Reports Positive TACTI-002 Data GlobeNewswire -5.28%
07:21AM  The Daily Biotech Pulse: FDA Snub For Merck, Priority Review For Roche's Tecentriq sBLA Benzinga
Feb-10-20 09:53PM  Here's What We Think About Immutep Limited's (ASX:IMM) CEO Pay Simply Wall St.
Feb-04-20 08:00AM  Immutep to Present TACTI-002 Interim Data at German Cancer Congress GlobeNewswire
Jan-29-20 08:00AM  Immutep Activities Report GlobeNewswire +20.00%
Jan-09-20 08:00AM  Immutep Expands Part C of TACTI-002 Due to Positive Data GlobeNewswire
Dec-19-19 08:00AM  INSIGHT-004 Clinical Trial Update GlobeNewswire -5.75%
Dec-11-19 06:48PM  Those Who Purchased Immutep (ASX:IMM) Shares Five Years Ago Have A 31% Loss To Show For It Simply Wall St.
Nov-14-19 08:00AM  Immutep Announces European Patent Grant for LAG525 Antibody GlobeNewswire
Nov-08-19 08:00AM  Immutep Presents Positive Interim Data From Phase II TACTI-002 Trial at SITC GlobeNewswire
Oct-28-19 08:00AM  Operational Update GlobeNewswire
Oct-15-19 08:00AM  Immutep Reports Positive Final Efficacy Data from TACTI-mel Trial in Melanoma GlobeNewswire +10.18%
07:50AM  The Daily Biotech Pulse: Reata Leaps On Positive Readout, Takeda Divests, FDA Nod For Akorn, J&J Earnings Benzinga
Oct-13-19 04:33PM  The Week Ahead In Biotech: FDA Decisions, Johnson & Johnson Among Big Pharma Earnings Benzinga
Oct-12-19 08:26PM  Immutep Limited (ASX:IMM): When Will It Breakeven? Simply Wall St.
Oct-10-19 08:00AM  Immutep Receives A$2.5 Million R&D Tax Incentive from French Government GlobeNewswire
08:00AM  Immutep Announces Data Presentations at Upcoming Industry Conferences GlobeNewswire
Sep-26-19 08:00AM  Immutep Announces Expansion of Part A of TACTI-002 Phase II Clinical Trial due to Positive Interim Data GlobeNewswire
Sep-23-19 08:00AM  Immutep to Receive £4M Milestone Payment From GSK GlobeNewswire +5.85%
Sep-17-19 08:00AM  Immutep Announces Japanese Patent Grant for LAG525 Antibody GlobeNewswire
Aug-28-19 09:15PM  Does Immutep Limited's (ASX:IMM) CEO Pay Reflect Performance? Simply Wall St.
Aug-22-19 08:00AM  Immutep Granted European Patent for Eftilagimod Alpha in Cancer GlobeNewswire
Aug-06-19 08:00AM  Immutep Completes A$6M Entitlement Offer GlobeNewswire +7.48%
Jul-26-19 08:00AM  Operational Update GlobeNewswire
Jul-10-19 07:17AM  The Daily Biotech Pulse: Jazz Buys Tumor Drug Program, Sanofi's BLA For Multiple Myeloma Drug Accepted, Positive Results For ViiV Benzinga
Jul-09-19 08:00AM  Immutep Raises A$10 Million Via Private Placement and Underwritten Entitlement Offer GlobeNewswire -11.36%
Jul-02-19 12:00PM  Edison Issues ADR Update On Immutep (IMMP) ACCESSWIRE
Jun-25-19 08:00AM  Immutep Completes Patient Enrolment of the AIPAC Phase IIb Clinical Trial in Metastatic Breast Cancer GlobeNewswire
Jun-24-19 02:36PM  Immutep to Host Key Opinion Leader Call GlobeNewswire
Jun-21-19 08:00AM  Immutep Announces Australian Patent Granted for Eftilagimod Alpha in Chemo-Immunotherapy GlobeNewswire
Jun-13-19 08:00AM  Immutep Completes Recruitment of Initial Cohort in 1st Line NSCLC Patients for TACTI-002 Trial GlobeNewswire
Jun-06-19 08:00AM  INSIGHT: First Patient Dosed in the 4th arm called INSIGHT-004 GlobeNewswire
Jun-03-19 08:00AM  Immutep Presentation at ASCO 2019 GlobeNewswire
May-26-19 11:04PM  What Kind Of Investor Owns Most Of Immutep Limited (ASX:IMM)? Simply Wall St.
May-23-19 08:00AM  Immutep Announces European Patent Grant for Eftilagimod Alpha in Chemo-Immunotherapy GlobeNewswire
May-17-19 08:00AM  Immutep Announces Data from Ongoing TACTI-mel Phase I Clinical Trial in Unresectable or Metastatic Melanoma GlobeNewswire
May-10-19 08:00AM  Immutep Announces Upcoming Industry Conference Participation GlobeNewswire
Apr-11-19 08:01PM  Immutep Limited (ASX:IMM): Are Analysts Optimistic? Simply Wall St.
Apr-08-19 01:55PM  Edison Issues ADR Update on Immutep (IMMP) ACCESSWIRE
Mar-27-19 11:19AM  Immutep to Host Eftilagimod Alpha Clinical Development Update Global Webcast GlobeNewswire
Mar-21-19 06:10PM  Immutep Announces United States Patent Grant for Eftilagimod Alpha in Cancer GlobeNewswire -6.86%
Mar-18-19 07:07PM  Immutep to Present IMP761 Preclinical Results in Global Webcast GlobeNewswire
Mar-07-19 04:30PM  Immutep Presents Positive IMP761 Preclinical Results at 14th Congress of European Crohns and Colitis Organisation GlobeNewswire
Mar-06-19 05:16PM  Immutep Shareholders Have Enjoyed A 52% Share Price Gain Simply Wall St.
08:00AM  Immutep doses First Patient in TACTI-002 Phase II Trial GlobeNewswire
08:00AM  Immutep Announces Data from Ongoing TACTI-mel Phase I Clinical Trial in Unresectable or Metastatic Melanoma GlobeNewswire
07:39AM  The Daily Biotech Pulse: Horizon Pharma Under DoJ Radar, FDA Greenlights J&J's Depression Drug, Endologix Reverse Split Benzinga
Mar-04-19 08:00AM  Immutep to Present at Oppenheimers 29th Annual Healthcare Conference GlobeNewswire
Feb-26-19 08:00AM  Immutep to Present at Upcoming Industry Conferences GlobeNewswire +9.14%
Feb-07-19 11:41AM  Honest Company co-founder Christopher Gavigan has a new, and newly funded, CBD startup called Prima TechCrunch
Jan-07-19 08:00AM  Immutep Enters Into Clinical Trial Collaboration, Service and Supply Agreement With CYTLIMIC GlobeNewswire
Dec-19-18 07:00AM  Immutep Announces US$5.2 Million Financing Led by U.S. Specialist Healthcare Investor, Altium Capital GlobeNewswire
Nov-27-18 08:00AM  New Data from Ongoing TACTI-mel Study in Unresectable or Metastatic Melanoma Presented at the 4th Annual ICI Europe Summit GlobeNewswire
Nov-22-18 07:50AM  Edison issues ADR update on Immutep (IMMP) GlobeNewswire
Nov-12-18 08:00AM  Immutep Presents Positive New Data from Ongoing TACTI-mel Study at Society for Immunotherapy of Cancer (SITC) 2018 Annual Meeting GlobeNewswire -7.14%
Nov-09-18 04:55PM  Gaming guide creator Prima Games is shutting down Engadget
Nov-01-18 08:00AM  Operational Update GlobeNewswire
Oct-30-18 08:30PM  Is Immutep Limited (ASX:IMM) Excessively Paying Its CEO? Simply Wall St.
Oct-24-18 08:00AM  Immutep Announces Data Presentations at Upcoming Industry Conferences GlobeNewswire -6.60%
Oct-02-18 08:00AM  Immutep Announces Presentations at Society for Immunotherapy of Cancer (SITC) 2018 Annual Meeting GlobeNewswire
Sep-27-18 04:36AM  Edison issues update on Immutep (IMMX) GlobeNewswire -6.18%
Sep-26-18 08:00AM  Immutep to Present at Ladenburg Thalmann 2018 Healthcare Conference GlobeNewswire
Sep-24-18 08:00AM  Immutep Enters Into Clinical Trial Collaboration and Supply Agreement With Merck KGaA, Darmstadt, Germany, and Pfizer GlobeNewswire +6.98%
Sep-03-18 08:00AM  Progress Towards Clinical Development of IMP761 a LAG-3 Agonist Antibody GlobeNewswire
Aug-21-18 04:44AM  Immutep Receives A$1.9 Million Research and Development Related Tax Rebate from French Government GlobeNewswire
Aug-16-18 08:00AM  Immutep to Present at the BioCentury 25th Annual NewsMakers in the Biotech Industry Conference GlobeNewswire
Aug-07-18 08:00AM  TACTI-mel Patient Recruitment Complete and Operational Update GlobeNewswire -6.62%
Jul-30-18 09:37PM  Immuteps LAG-3 Immunostimulant Product Candidate, Efti, Receives IND Approval From U.S. FDA GlobeNewswire
Jul-02-18 08:00AM  Immutep Submits Investigational New Drug (IND) Application With FDA GlobeNewswire
Jun-06-18 07:40AM  Research Report Identifies Diodes, Arbutus Biopharma, Radware, Immutep, Amarin, and SPS Commerce with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
May-30-18 08:00AM  Positive New Data from Ongoing TACTI-mel Study in Unresectable or Metastatic Melanoma Presented in Global Webcast GlobeNewswire +10.00%
May-17-18 08:00AM  Immutep to Present Interim Results from TACTI-mel Clinical Trial in Global Webcast GlobeNewswire
May-04-18 04:00AM  Immutep to Present at 2018 ASCO Annual Meeting GlobeNewswire
Apr-13-18 07:45AM  Investor Expectations to Drive Momentum within Criteo S.A, Prima BioMed, CoStar Group, DBV Technologies S.A, Hollysys Automation Technologies, and China Biologic Products Discovering Underlying Factors of Influence GlobeNewswire
Apr-12-18 09:24PM  Immutep Completes A$6.31 Million Share Purchase Plan; Raises Total of A$13.16 Million GlobeNewswire
Apr-02-18 08:38PM  Operational Update GlobeNewswire
Mar-29-18 10:30AM  Edison Issues Update on Immutep (IMMP) ACCESSWIRE
Mar-22-18 07:45PM  Updated TACTI-mel Data Presented at the Cambridge Healthtech Institutes Immuno-Oncology Summit GlobeNewswire
Mar-21-18 06:29PM  Immutep Commences Patient Dosing in Additional TACTI-mel Cohort GlobeNewswire
Mar-16-18 08:10AM  New Research Coverage Highlights Amarin, Corbus Pharmaceuticals, Green Brick Partners, Immutep, Texas Capital Bancshares, and G1 THERAPEUTICS Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Mar-11-18 07:55PM  Immutep Raises A$6.85m Through Institutional Placement GlobeNewswire
07:25PM  Immutep Enters Into Clinical Trial Collaboration and Supply Agreement With MSD GlobeNewswire
Mar-05-18 10:54PM  Immutep Announces United States Patent Grant for IMP701 Antibody GlobeNewswire
Mar-04-18 10:27PM  Immutep receives A$686,704 R&D Tax Incentive GlobeNewswire
Feb-08-18 07:55PM  Outcome from DSMB Safety Review and Extension of TACTI-mel Phase I Clinical Trial GlobeNewswire
Jan-31-18 10:01PM  Immutep Limited Announces Milestone Payment From Chinese Partner EOC Pharma GlobeNewswire
Nov-27-17 07:12PM  Prima BioMed Becomes Immutep GlobeNewswire
Immutep Limited, a biotechnology company, engages in the research, development, and commercialization of biological products. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its therapeutics are based on the lymphocyte activation gene-3 (LAG-3) Ig fusion protein, a cell surface molecule that plays a role in regulating T cells. The company's lead product candidate is eftilagimod alpha (efti), an antigen presenting cell activator, which is in a Phase IIb clinical trial as a chemoimmunotherapy for metastatic breast cancer. Its other products include TACTI-002, a combination of efti with KEYTRUDA that is in a Phase II clinical trial for solid tumors; INSIGHT-004, a human anti-PD-L1 antibody, which is in a Phase I clinical trial to evaluate a combination of efti with avelumab; and TACTI-mel that is in a Phase I clinical trial for metastatic melanoma. The company also develops IMP761 for autoimmune disease. It has operations in Europe, Australia, and the United States. Immutep Limited has a clinical trial collaboration and supply agreements with Merck KGaA, Darmstadt, Germany, and Pfizer Inc.; and partnerships with GlaxoSmithKline, Novartis, CYTLIMIC, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited is headquartered in Sydney, Australia.